met resistance mutations

NVP-BVU972 is a selective and potent Met inhibitor with IC50 of 14 nM.

MET Transcription-IN-1 (Compound C3) is an orally active inhibitor of MET transcription that efficiently binds to and stabilizes the G-quadruplex in the MET promoter region, thereby inhibiting c-Met expression. It can overcome resistance caused by specific c-Met mutations and effectively inhibits tumor cell proliferation, migration, and invasion, inducing cell cycle arrest and apoptosis. This compound exhibits antitumor activity and is applicable in the study of tumors such as non-small cell lung cancer.

KIN-8741 is a highly selective and orally active Type IIb c-Met inhibitor. It exhibits broad-spectrum activity against c-Met kinase mutations. KIN-8741 demonstrates antitumor activity in non-small cell lung cancer models with MET gene amplification and exon 14 deletion. It is applicable in research on c-Met-driven cancers, particularly advanced tumors harboring MET exon 14 skipping mutations and acquired resistance mutations.